Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pacira BioSciences Narrows FY2025 Sales Guidance from $725.000M-$765.000M to $730.000M-$750.000M vs $739.059M Est

Author: Benzinga Newsdesk | August 05, 2025 04:02pm
Pacira BioSciences (NASDAQ:PCRX) narrows FY2025 sales outlook from $725.000 million-$765.000 million to $730.000 million-$750.000 million vs $739.059 million estimate.

Posted In: PCRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist